XBiotech Inc. (XBIT): Nasdaq/NYSE listing notice — Director W. Thorpe McKenzie retires; XBiotech to maintain one-member audit and compensation committees

XBiotech Inc.

W. Thorpe McKenzie retired from the Board effective March 27, 2025.
Company notified NASDAQ on April 1, 2025, of the retirement and intent to fill vacancies.
Audit Committee and Compensation Committee will each operate with one member under NASDAQ exceptions.
Vacancies to be filled within the time prescribed by NASDAQ Rules 5605(c)(4) and 5605(d)(4).

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

XBiotech Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(4), 5605(d)(4)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: audit committee
Rules: 5605(c)(4), 5605(d)(4)

Exact text from the filing

April 1, 2025, W. Thorpe McKenzie retired from the Company’s Board of Directors effective March 27, 2025. Independent director Jan-Paul Waldin will continue to serve as a member of the Company’s Audit Committee and Compensation Committee. The Company intends to maintain a one-member Audit Committee at this time pursuant to Rule 5605(c)(4) of the NASDAQ Listed Company Manual and a one-member Compensation Committee at this time pursuant to Rule 5605(d)(4) of the NASDAQ Listed Company Manual. On April 1, 2025, the Company notified NASDAQ regarding Mr. McKenzie’s retirement and the Company’s inten

View on SEC.gov

Browse all listing & compliance notices →

XBiotech Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-002067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.